Sarah Gilbert
#19,022
Most Influential Person Now
British vaccinologist
Sarah Gilbert's AcademicInfluence.com Rankings
Sarah Gilbertbiology Degrees
Biology
#2250
World Rank
#3602
Historical Rank
Biochemistry
#510
World Rank
#598
Historical Rank
Sarah Gilbertphilosophy Degrees
Philosophy
#5185
World Rank
#7921
Historical Rank
Logic
#3992
World Rank
#5231
Historical Rank
Download Badge
Biology Philosophy
Sarah Gilbert's Degrees
- Bachelors Biological Sciences University of East Anglia
Why Is Sarah Gilbert Influential?
(Suggest an Edit or Addition)According to Wikipedia, Dame Sarah Catherine Gilbert FRS is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.
Sarah Gilbert's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (2020) (3297)
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020) (1480)
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020) (1079)
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (2021) (937)
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) (850)
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (2021) (812)
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2020) (733)
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection (2021) (730)
- Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara (1998) (718)
- Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans (2004) (622)
- Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans (2003) (607)
- Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (2021) (576)
- Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria (1995) (566)
- Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) (427)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021) (404)
- Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. (2005) (399)
- Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 (2011) (385)
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera (2021) (373)
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2020) (367)
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. (2015) (295)
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity (2012) (295)
- Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation (2013) (281)
- Association of malaria parasite population structure, HLA, and immunological antagonism. (1998) (281)
- Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. (2005) (262)
- ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques (2020) (261)
- Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria (2008) (251)
- Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis (2001) (250)
- Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans (2012) (247)
- Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis (2009) (239)
- Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. (1998) (237)
- Fluorescent proteins at a glance (2011) (234)
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2020) (228)
- Prime-boost vectored malaria vaccines: Progress and prospects (2010) (217)
- MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques (2009) (215)
- Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector (2012) (207)
- Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies (1999) (205)
- ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. (2012) (193)
- Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses (2009) (187)
- Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. (2002) (183)
- Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1 (2002) (181)
- A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults (2004) (176)
- Effective induction of high-titer antibodies by viral vector vaccines (2008) (171)
- Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers1 (2005) (170)
- A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge (2006) (168)
- Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens (2013) (167)
- Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. (2005) (164)
- A protein particle vaccine containing multiple malaria epitopes (1997) (163)
- Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. (2011) (161)
- Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors (2012) (160)
- A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya (2006) (157)
- DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. (1998) (152)
- Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. (1998) (151)
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) (2021) (150)
- Clinical development of Modified Vaccinia virus Ankara vaccines. (2013) (149)
- Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass (2010) (146)
- Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes. (2006) (140)
- Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (2020) (138)
- T‐cell‐inducing vaccines – what’s the future (2012) (137)
- Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria1 (2005) (136)
- ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice (2017) (136)
- Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models (2021) (124)
- Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine (2017) (123)
- A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years (2012) (123)
- Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals (2014) (121)
- Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. (2004) (121)
- Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. (2006) (120)
- Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial (2008) (119)
- Progression of Plasmodium berghei through Anopheles stephensi Is Density-Dependent (2007) (118)
- Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. (1999) (117)
- Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density (2006) (117)
- Cellular immune responses induced in cattle by heterologous prime–boost vaccination using recombinant viruses and bacille Calmette–Guérin (2004) (114)
- Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. (2005) (113)
- Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs (2005) (108)
- Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. (2014) (108)
- Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. (2003) (108)
- Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming (1999) (107)
- Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus1 (2004) (106)
- Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults (2018) (105)
- Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance1 (2005) (105)
- Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization (1996) (103)
- Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes1 (2006) (103)
- Single‐dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei (2008) (101)
- Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. (2003) (100)
- Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum (2015) (99)
- Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. (2014) (96)
- Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa (2021) (96)
- A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. (2006) (95)
- Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I‐restricted epitope with recombinant carriers suitable for human use (1998) (93)
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial (2021) (93)
- Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence (2005) (93)
- The Induction and Persistence of T Cell IFN-γ Responses after Vaccination or Natural Exposure Is Suppressed by Plasmodium falciparum1 (2007) (93)
- Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. (2006) (90)
- Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever (2016) (90)
- Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. (1998) (89)
- Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines (2010) (89)
- Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA) (2008) (85)
- Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice (2021) (85)
- Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. (2009) (84)
- Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909 (2011) (84)
- Characterization of the Fine Specificity of Bovine CD8 T-Cell Responses to Defined Antigens from the Protozoan Parasite Theileria parva (2007) (83)
- Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics (2021) (83)
- A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques (2020) (82)
- Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP (2016) (81)
- Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. (2005) (81)
- Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults (2013) (80)
- Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model (2017) (80)
- A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. (2001) (78)
- Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 (2020) (77)
- Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya (2007) (76)
- Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein (2006) (73)
- Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1 (2013) (73)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (2021) (72)
- A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses (2003) (71)
- Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1☆ (2010) (71)
- Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A (2008) (71)
- Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice (2013) (69)
- Human leukocyte antigens and natural selection by malaria. (1994) (69)
- Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity1 (2005) (68)
- Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels (2019) (68)
- Genetic analysis of host-parasite coevolution in human malaria. (1997) (67)
- Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors (2018) (66)
- Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 (2020) (66)
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial (2021) (65)
- What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins (2016) (65)
- Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria (2011) (65)
- Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes (2006) (64)
- Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. (2014) (61)
- Simian adenoviruses as vaccine vectors (2016) (61)
- Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine (2021) (61)
- Examination of Influenza Specific T Cell Responses after Influenza Virus Challenge in Individuals Vaccinated with MVA-NP+M1 Vaccine (2013) (60)
- Chimpanzee adenoviral vectors as vaccines for outbreak pathogens (2017) (59)
- CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells (2020) (57)
- Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1 (2011) (56)
- New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1 (2010) (54)
- Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. (2006) (53)
- A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice (2020) (53)
- Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine (2021) (53)
- Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3 (2000) (53)
- The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus (2011) (53)
- A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS (2014) (53)
- Utilizing poxviral vectored vaccines for antibody induction—Progress and prospects (2013) (51)
- Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice (2013) (51)
- Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal (2018) (50)
- Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. (2014) (50)
- A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine (2011) (49)
- Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates (2012) (49)
- Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. (2006) (49)
- Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection (2013) (48)
- Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus (2013) (45)
- A Single Immunization with MVA Expressing GnGc Glycoproteins Promotes Epitope-specific CD8+-T Cell Activation and Protects Immune-competent Mice against a Lethal RVFV Infection (2013) (45)
- Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques (2021) (45)
- Operation Warp Speed: implications for global vaccine security (2021) (44)
- Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference (2011) (42)
- Modified Vaccinia Virus Ankara-Based Vaccine Vectors Induce Apoptosis in Dendritic Cells Draining from the Skin via both the Extrinsic and Intrinsic Caspase Pathways, Preventing Efficient Antigen Presentation (2012) (42)
- Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors (2012) (41)
- Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. (2011) (41)
- Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine (2013) (40)
- Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. (2015) (39)
- Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge (2019) (39)
- Heterologous Priming-Boosting Immunization of Cattle with Mycobacterium tuberculosis 85A Induces Antigen-Specific T-Cell Responses (2003) (38)
- Ty Virus-Like Particles, DNA Vaccines and Modified Vaccinia Virus Ankara; Comparisons and Combinations (1999) (38)
- Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP (2018) (37)
- Correcting COVID-19 vaccine misinformation (2021) (37)
- Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies (2015) (37)
- Differential Effects of Viral Vectors on Migratory Afferent Lymph Dendritic Cells In Vitro Predict Enhanced Immunogenicity In Vivo (2011) (36)
- Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 (2021) (36)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil (2021) (35)
- A Multi-Antigenic Adenoviral-Vectored Vaccine Improves BCG-Induced Protection of Goats against Pulmonary Tuberculosis Infection and Prevents Disease Progression (2013) (35)
- The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment (2013) (35)
- A Novel Multi-Antigen Virally Vectored Vaccine against Mycobacterium avium Subspecies paratuberculosis (2007) (34)
- Vaccine platforms for the prevention of Lassa fever (2019) (33)
- ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 (2021) (33)
- A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters (2019) (33)
- Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals (2006) (33)
- Transcriptomic profiling facilitates classification of response to influenza challenge (2014) (33)
- DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. (2000) (32)
- SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription (2021) (32)
- Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice (2015) (31)
- Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP (2018) (31)
- Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. (2006) (31)
- Recombinant modified vaccinia virus Ankara-based malaria vaccines (2015) (31)
- Advances in the development of universal influenza vaccines (2012) (30)
- (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111. (2020) (29)
- Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic (2021) (28)
- Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice (2019) (28)
- External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance (2014) (28)
- Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. (2007) (28)
- Alternating vector immunizations encoding pre‐erythrocytic malaria antigens enhance memory responses in a malaria endemic area (2006) (28)
- Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology (2017) (27)
- Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis (2011) (27)
- Improved method for distinguishing the human source of mosquito blood meals between close family members. (2000) (27)
- Adenoviral vectors as novel vaccines for influenza (2015) (26)
- Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) (2021) (26)
- Virus-like particles as vaccine adjuvants (2001) (26)
- ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets (2021) (26)
- A naturally protective epitope of limited variability as an influenza vaccine target (2018) (25)
- ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 (2021) (25)
- Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line (2019) (24)
- Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA (2012) (24)
- Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. (2009) (24)
- Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats (2019) (24)
- Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components (2019) (23)
- Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs. (2014) (23)
- Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. (2010) (23)
- The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species (2015) (22)
- Migratory sub-populations of afferent lymphatic dendritic cells differ in their interactions with Mycobacterium bovis Bacille Calmette Guerin. (2012) (22)
- Dopamine receptors in human embryonic stem cell neurodifferentiation. (2013) (22)
- T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent–inactivated Influenza Vaccine (2012) (22)
- The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies (2021) (21)
- Recombinant Viral-Vectored Vaccines Expressing Plasmodium chabaudi AS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection (2012) (21)
- Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria (2009) (21)
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2020) (20)
- Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine (2019) (20)
- Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. (2004) (19)
- Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs (2021) (19)
- Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV (2022) (19)
- Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques (2021) (19)
- Adenovirus-vectored Ebola vaccines (2015) (18)
- ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge (2021) (18)
- Poxvirus vectors. (2013) (17)
- Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines. (2016) (17)
- Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge (2017) (17)
- Effect of dose and route of immunisation on the immune response induced in cattle by heterologous Bacille Calmette-Guerin priming and recombinant adenoviral vector boosting. (2014) (16)
- Anti-CD 25 Antibody Enhancement of Vaccine-Induced Immunogenicity : Increased Durable Cellular Immunity with Reduced Immunodominance 1 (2005) (16)
- Immunity, safety and protection of an Adenovirus 5 prime - Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves (2014) (16)
- Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults (2012) (16)
- A single dose of ChAdOx1 MERS provides broad protective immunity against a variety of MERS-CoV strains (2020) (15)
- Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector. (2017) (15)
- Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2021) (15)
- Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial (2021) (15)
- Inverse Associations of Human Leukocyte Antigen and Malaria Parasite Types in Two West African Populations (2005) (15)
- Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. (2016) (14)
- Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination (2016) (14)
- An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8+ central memory T cells and confers partial protection against a lethal challenge (2018) (14)
- Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus. (2019) (13)
- Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity (2015) (13)
- ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models (2021) (13)
- Does Melanoma Begin in a Melanocyte Stem Cell? (2012) (13)
- Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus (2020) (12)
- A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol (2019) (12)
- Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity (2021) (12)
- Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model (2022) (12)
- Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies☆ (2012) (11)
- Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers (2019) (11)
- Protein particle vaccines against malaria. (1997) (11)
- Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid‐encoded cytokines against Mycobacterium bovis (2010) (11)
- Erratum: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans (2004) (10)
- Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid (2016) (10)
- Fluorescent proteins at a glance (2011) (10)
- Prime-boost immunisation against tropical theileriosis with two parasite surface antigens: evidence for protection and antigen synergy. (2011) (10)
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2021) (10)
- Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection (2021) (10)
- UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments (2019) (10)
- Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis (2011) (9)
- Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP (2016) (9)
- A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector (2020) (9)
- Anti-CD25 antibody enhancement of vaccine-induced immunogenicity to bacterial, viral and parasitic antigens: increased durable cellular immunity with reduced immunodominance (2005) (9)
- Correction: Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial (2011) (8)
- Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment (2021) (8)
- ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants (2022) (8)
- ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV (2021) (7)
- Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule (2020) (7)
- Urgent needs to accelerate the race for COVID-19 therapeutics (2021) (7)
- Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial (2022) (7)
- Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. (2022) (6)
- 4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques (2014) (6)
- Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines (2013) (6)
- MVA-NP+M1 vaccine activates mucosal M1-specific T cell immunity and tissue-resident memory T cells in human nasopharynx-associated lymphoid tissue. (2019) (6)
- Vaccines That Reduce Viral Shedding Do Not Prevent Transmission of H1N1 Pandemic 2009 Swine Influenza A Virus Infection to Unvaccinated Pigs (2020) (6)
- Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed (2021) (6)
- Viral vectored transmission blocking vaccines against Plasmodium falciparum (2010) (6)
- Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility (2022) (6)
- Influenza vaccines and immunopathology (2012) (6)
- Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses (2011) (6)
- Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials (2017) (5)
- Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies (2021) (5)
- Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques (2020) (5)
- ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models (2021) (5)
- Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154] (2018) (5)
- Modified Vaccinia Ankara–Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue (2019) (5)
- SARS-CoV-2 candidate vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals a normal low range of viral backbone gene expression alongside very high levels of SARS-CoV-2 S glycoprotein expression. (2020) (5)
- Heterologous vaccination regimens with self-amplifying RNA and Adenoviral 1 COVID vaccines induce superior immune responses than single dose vaccine 2 regimens in mice 3 (2021) (5)
- Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus (2022) (5)
- CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination (2022) (4)
- The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge (2021) (4)
- Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment (2022) (4)
- Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS) (2021) (4)
- Recombinant protein vaccines against SARS-CoV-2 (2021) (4)
- New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1 (2011) (4)
- Emergency Ebola response. a new approach to the rapid design and development of vaccines against emerging diseases (vol 15, pg 356, 2015) (2015) (4)
- Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses (2021) (4)
- Indigenous ways: assessing the awareness of and potential need for identifying content on indigenous world view in educating Libraries/Archives/Museum (LAM) entry level professionals (2013) (3)
- pSG.MEPfTRAP – A First Generation Malaria DNA Vaccine Vector (2007) (3)
- Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice (2021) (3)
- Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154] (S2352396418300653) (10.1016/j.ebiom.2018.02.011)) (2018) (3)
- Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs (2021) (3)
- An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females (2022) (3)
- Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies (2021) (3)
- Development and use of lentiviral vectors pseudotyped with influenza B haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies (2018) (2)
- Influenza vaccines: Where do we stand? Where do we go?: A bumpy but steady road upwards. (2015) (2)
- Practical Considerations for Conducting Job Analysis Linkage Exercises (2018) (2)
- Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2021) (2)
- Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908] (2005) (2)
- The SPf66 Malaria Vaccine: Where Do We Go From Here? (1998) (2)
- HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT (2017) (2)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021) (2)
- Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility (2021) (2)
- Incidental Diagnosis in Healthy Clinical Trial Subjects (2012) (2)
- Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters (2022) (2)
- Wanted: UX Specialist with Reference Preparation or Reference Classes Assist Students in Preparing for UX Careers (2018) (2)
- Replication Defective Adenovirus Serotype 5 Expressing Marek ’ s Disease Virus Envelope Glycoprotein as a Potential Marek ’ s Disease Vaccine in Chicken (2017) (2)
- Expanding the Malaria Antibody Toolkit: Development and Characterisation of Plasmodium falciparum RH5, CyRPA, and CSP Recombinant Human Monoclonal Antibodies (2022) (2)
- In search of a vaccine (2005) (1)
- Development of low bio-containment assays to characterise the antibody responses in pigs to Nipah virus vaccine candidates (2019) (1)
- A potent neutralizing epitope of limited variability in the head domain of haemagglutinin as a novel influenza vaccine target (2018) (1)
- Alcock Vectors at Supraphysiological Temperatures in Carbohydrate Glass Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine (2010) (1)
- Transcriptomic Profiling of Dromedary Camels Immunised with a MERS Vaccine Candidate (2021) (1)
- Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice (2013) (1)
- Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs (2023) (1)
- No one is safe until we are all safe (2021) (1)
- Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels (2022) (1)
- Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping (2015) (1)
- T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa (2022) (1)
- ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys (2021) (1)
- T Cell Inducing Vaccines (2015) (1)
- Tackling human and animal health threats through innovative vaccinology in Africa. (2018) (1)
- Corrections. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. (2015) (1)
- Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. (2023) (1)
- ailoring subunit vaccine immunogenicity : Maximizing antibody and T cell esponses by using combinations of adenovirus , poxvirus and protein-adjuvant accines against Plasmodium falciparum MSP 1 (2010) (1)
- Identification of an epitope of limited variability under strong immune selection in the haemagglutinin head domain of H1N1 influenza (2017) (1)
- Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern (2022) (1)
- An epitope of limited variability as a novel influenza vaccine target (2017) (1)
- Methods and reagents for production of a CD8 + T cell immune response (1998) (0)
- Polymorphism in the circumsporozoite protein of Plasmodium falciparum: A novel immune evasion strategy (1997) (0)
- MVA-based vectors induce apoptosis in DC draining the skin via the extrinsic and intrinsic caspase pathways preventing efficient antigen presentation (2012) (0)
- Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report (2022) (0)
- A naturally protective epitope of limited variability as an influenza vaccine target (2018) (0)
- ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge (2021) (0)
- Immunodominance Durable Cellular Immunity with Reduced Vaccine-Induced Immunogenicity : Increased Anti-CD 25 Antibody Enhancement of HillKatherine (2005) (0)
- Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2021) (0)
- No easy route to a pandemic influenza vaccine. (2013) (0)
- Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial (2022) (0)
- Vaccination Protocols Immune Response Induced by Prime-Boost Competition Between CTL Narrows the (2002) (0)
- Immunity to mycobacterial infection (PP-061) (2010) (0)
- Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species (2011) (0)
- Recombinant Adenovirus Overcome by Prior Immunization with a Efficacy of Protein Vaccines Can Be Enhance the Immunogenicity and Protective The Requirement for Potent Adjuvants To (2011) (0)
- Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule (2020) (0)
- Immunogenicity of a pre-erythrocytic-stage malaria insert ME-trap encoded by novel simian adenoviral vectors (2005) (0)
- Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs (2011) (0)
- P.4.01.21 perspective of vaccine1 prophylaxis of pyoseptic complications (1997) (0)
- Vaccination and immunotherapy of viral diseases (PP-069) (2010) (0)
- Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model (2023) (0)
- Correlate with Parasitological and Clinical Plasmodium falciparum to Blood-Stage Malaria : Heterogeneous Cytokine Responses Innate Immune Responses to Human Sinden (2006) (0)
- Statistical modelling of data showing pandemic H1N1 2009 swine influenza a virus infection kinetics in vaccinated pigs. (2019) (0)
- DNA immunisation of mice with Plasmodium berghei antigens: Use of whole antigens or multi-epitope strings, boosting with vaccinia and protection against challenge (1997) (0)
- Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials (2023) (0)
- Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials (2017) (0)
- Humoral and Cell-Mediated Immunity Combinations for Simultaneous Induction of Novel Protein and Poxvirus-Based Vaccine (2005) (0)
- Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats (2019) (0)
- Enhanced immunogenicity for CTL induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara encoding pre-erythrocytic (1997) (0)
- Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP (2018) (0)
- Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model (2017) (0)
- Why acute inflammatory response can happen after Adenoviral Vector Vaccines; Is the interleukin 6 the secret and how circumvent that, Is by adding polyethylene glycol (PEG)? (2021) (0)
- CD4+ T follicular helper (Tfh) cells in human tonsil and blood are clonally convergent, but divergent from non-Tfh CD4+ cells (2019) (0)
- Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies. (2021) (0)
- MERS-CoV Spike Glycoprotein (GP) – ELISA Jenner Clinical SOP Template v1 (2020) (0)
- Evaluating the Ad5/MVA antigen delivery systems (2015) (0)
- Vaccination and immunotherapy against bacteria, fungi and parasites (PP-048) (2010) (0)
- CLINICAL DEVELOPMENT OF VIRAL VECTORED VACCINES AGAINST MERS-COV (2018) (0)
- Statistical modelling of data showing pandemic H1N1 2009 swine in fl uenza a virus infection kinetics in vaccinated pigs Data in brief (2019) (0)
- Using pox virus vector lacking replica to boost CD4 + T cell immune response to the antigen. (2001) (0)
- DNA- and MVA-based multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice and macaques (1997) (0)
- Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP (2018) (0)
- Transcriptomic profiling facilitates classification of response to influenza challenge (2014) (0)
- IDENTIFICATION OF HUMAN T CELL EPITOPES IN THE EBOLAVIRUS GLYCOPROTEIN FOLLOWING VACCINATION WITH CHAD3 EBO Z GP AND MVA BN (2017) (0)
- of a Novel Heterosubtypic Influenza A Vaccine, MVA2NP1M1 (2011) (0)
- NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS (2009) (0)
- Characterising immune responses to viral vectored vaccines against influenza and hepatitis C (2014) (0)
- Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA) (2011) (0)
- Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination (2023) (0)
- Methods and reagents for production of a CD8 + T cell immune response to hepatitis B or C (1998) (0)
- Novel MVA-based vaccine expressing influenza NP and M1 activates cross-reactive T cell responses in human nasopharynx-associated lymphoid tissue (NALT) (2018) (0)
- Efficacy of Primary Series AZD1222 (ChAdOx1 nCoV-19) Vaccination Against SARS-CoV-2 Variants of Concern: Final Analysis of a Randomized, Placebo-controlled, Phase 1b/2 Study in South African Adults (COV005) (2023) (0)
- Attenuated Fowlpox Virus Immunization Regimens Using a Novel Malaria by Prime Boost berghei Plasmodium and Protection Elicited against T Cell Immune Responses + Enhanced CD8 (2004) (0)
- DNA followed by recombinant Vaccinia induces cellular and humoral immune responses against a pre-erythrocytic antigen of Plasmodium falciparum in chimpanzees (1997) (0)
- Evaluation of simian adenoviral vector AdCh63 expressing MSP-1 as a candidate blood-stage malaria vaccine (2009) (0)
- Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults (2015) (0)
- Rapid, cost-effective and scalable gmp-compliant simian adenovirus-vectored vaccine production for early-phase clinical trials using entirely disposable product-contact components (2018) (0)
- SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription (2021) (0)
- Fusion of the Mycobacteriumtuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates (2012) (0)
- Is Suppressed by Responses after Vaccination or Natural Exposure γ The Induction and Persistence of T Cell IFN (2011) (0)
- The Search for a Malaria Vaccine: Clinical Trials of DNA-MVA and other Prime-Boost Approaches (2003) (0)
- Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies (2015) (0)
- An adenoviral model to unlock the secrets of memory inflation (2013) (0)
- Building a Repository to Support Research on Emerging Pathogens: How to Use the Experience of the Centre for AIDS Reagents (2020) (0)
- Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors (2018) (0)
- Effect of adenovirus dose and prime-boost interval on the immune kinetics of the effector immune response (2005) (0)
- Repertoire sharing between CD4(+) T follicular helper cells in peripheral blood and tonsil (2019) (0)
- Tackling human and animal health threats through innovative vaccinology in Africa (2018) (0)
- Session 7: Observing immunity: implications for rational vaccine design (2004) (0)
- Using DNA and Viral Vectors in Healthy Heterologous Prime-Boost Vaccine Regimens Differential Immunogenicity of Various (2004) (0)
- Immunogenicity and protection of the Theileria parva CTL antigen Tp1, with or without a leader sequence, using HAd5/MVA prime-boost vaccination (2016) (0)
- Methods and reagents for production of a CD8 + T cell immune response against Melanoma (1998) (0)
- An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8+ central memory T cells and confers partial protection against a lethal challenge (2018) (0)
- falciparum Plasmodium Exposure Is Suppressed by Responses after Vaccination or Natural γ The Induction and Persistence of T Cell IFN-and (2007) (0)
- Correction: MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques (2011) (0)
- Protection from Plasmodium berghei infection by priming to a single CTL epitope with vaccine carriers that do not require adjuvants (1997) (0)
- Evaluating the potential of novel virus-vectored vaccines as intranasal vaccine candidates for broad immunity against influenza (2015) (0)
- New vectored vaccines for malaria. (2008) (0)
- Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions (2022) (0)
- Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial (2023) (0)
- Development of a CTL inducing vaccine against plasmodium falciparum using a combination of delivery systems (1998) (0)
This paper list is powered by the following services:
Other Resources About Sarah Gilbert
What Schools Are Affiliated With Sarah Gilbert?
Sarah Gilbert is affiliated with the following schools:
